Multiple Myeloma Clinical Trial
— RETROOfficial title:
Retrospective Study of the First-line Treatment of Patients With Newly Diagnosed Transplant-ineligible Multiple Myeloma Between 2012 and 2016, Treated According to Routine Clinical Practice in Spain
Verified date | January 2019 |
Source | Celgene |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This is an observational, post-authorization, retrospective, multicenter study (PAS-OD) that will be conducted in approximately 20 centers in Spain. In all cases, only data recorded prior to the date of study start will be collected to ensure its retrospective nature, thus reflecting real clinical practice, avoiding any influence on the physician's clinical practice.
Status | Completed |
Enrollment | 706 |
Est. completion date | January 18, 2019 |
Est. primary completion date | January 18, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patients aged = 18 years - Patients with newly diagnosed MM who were not suitable candidates for ASCT who started anti-myeloma treatment between 2012 and 2016, inclusive. - Patients who give informed consent before data collection begins. Exclusion Criteria: - Patients who participated in a clinical trial for first-line treatment of MM during the study period. - Patients who are alive, but do not give their IC. - Patients with MM who did not receive treatment. |
Country | Name | City | State |
---|---|---|---|
Spain | H. del Mar | Barcelona | |
Spain | H. Cabueñes | Gijón | Asturias |
Spain | H. Josep Trueta | Girona | |
Spain | H. Jerez | Jerez de la Frontera | Cadiz |
Spain | ICO Duran i Reynals | L'Hospitalet de Llobregat | Barcelona |
Spain | H. Arnau de Villanova | Lleida | |
Spain | H- Virgen de la Victoria | Malaga | |
Spain | H. Carlos Haya | Malaga | |
Spain | H. Althaia | Manresa | Barcelona |
Spain | H. Ourense (CHOU) | Orense | |
Spain | H. Central de Asturias | Oviedo | Asturias |
Spain | H. Son Espases | Palma | Baleares |
Spain | H. Santiago (CHUS) | Santiago de Compostela | A Coruña |
Spain | H. Virgen Macarena | Sevilla | |
Spain | H. Joan XXIII | Tarragona | |
Spain | H. Mutua de Terrassa | Terrasa | Barcelona |
Spain | H. Dr. Peset | Valencia | |
Spain | H. La Fe | Valencia | |
Spain | H. Alvaro Cunqueiro | Vigo | Pontevedra |
Spain | H. Txagorritxu | Vitoria | Alava |
Lead Sponsor | Collaborator |
---|---|
Celgene |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Description of the first-line treatment regimens | Number of patients in the different first-line treatment regimens, in terms of the main drug used in patients diagnosed de novo with MM who were not candidates for autologous stem cell transplantation (ASCT) | Up to approximately 5 months | |
Secondary | Description of the characteristics of patients with a diagnosis of MM who were not candidates for ASCT in Spain | Number of patients with a diagnosis of MM who were not candidates for ASCT in Spain in each staging group: Stage I, II and III (ISS) and ISS R | Up to approximately 5 months | |
Secondary | Description of the characteristics of patients with a diagnosis of MM who were not candidates for ASCT in Spain | Number of patients with a diagnosis of MM who were not candidates for ASCT in Spain in each MM subtype group | Up to approximately 5 months | |
Secondary | Progression-free survival (PFS) | Is described as time from start of treatment until disease progression or death | Up to approximately 5 months | |
Secondary | Overall survival (OS) | Is described as time from start of the treatment until death | Up to approximately 5 months | |
Secondary | Overall response rate | Is based on IMWG criteria | Up to approximately 5 months | |
Secondary | Duration of response | Is described as time from start of the treatment until end of first line treatment | Up to approximately 5 months | |
Secondary | Patients who receive second-line treatment | Proportion of patients who receive second-line treatment | Up to approximately 5 months | |
Secondary | Patients who underwent dose adjustment or switched treatment | Proportion of patients who underwent dose adjustment or switched treatment | Up to approximately 5 months | |
Secondary | Patients who discontinued treatment | Proportion of patients who discontinued treatment | Up to approximately 5 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05027594 -
Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02412878 -
Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma
|
Phase 3 | |
Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05971056 -
Providing Cancer Care Closer to Home for Patients With Multiple Myeloma
|
N/A | |
Recruiting |
NCT05243797 -
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
|
Phase 3 | |
Active, not recruiting |
NCT04555551 -
MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
|
Phase 1 | |
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Completed |
NCT02916979 -
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
|
Phase 1 | |
Recruiting |
NCT03570983 -
A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion
|
Phase 2 | |
Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
Completed |
NCT03665155 -
First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody
|
Phase 1/Phase 2 | |
Completed |
NCT02812706 -
Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05024045 -
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
|
Phase 1 | |
Active, not recruiting |
NCT03989414 -
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03792763 -
Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients
|
Phase 2 | |
Withdrawn |
NCT03608501 -
A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation
|
Phase 2 | |
Recruiting |
NCT04537442 -
Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02546167 -
CART-BCMA Cells for Multiple Myeloma
|
Phase 1 |